Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

INvestigating the Lowest Threshold of Vascular bENefits From LDL Cholesterol Lowering With a PCSK9 mAb InhibiTor (Alirocumab) in healthY Volunteers

NCT03273972 is registered in ClinicalTrials.gov with Cambridge University Hospitals NHS Foundation Trust as lead sponsor.

NCT NCT03273972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03273972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
INvestigating the Lowest Threshold of Vascular bENefits From LDL Cholesterol Lowering With a PCSK9 mAb InhibiTor (Alirocumab) in healthY Volunteers
Lead sponsor
Cambridge University Hospitals NHS Foundation Trust
Phase
Not applicable
Overall status
Completed
Start date
September 7, 2017
Completion date
October 10, 2018
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerosis, cardiovascular diseases